{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120706","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.837081+00:00","generated_at":"2026-05-30T06:02:26.047655+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fractyl Health nominates RJVA-002 GIP/GLP-1 gene therapy; positive 13-week preclinical data on RJVA-001","bullets":["Nominated RJVA-002 as first GIP/GLP-1 pancreatic gene therapy lead candidate for obesity.","RJVA-001 shows sustained weight and blood sugar control at 13 weeks in DIO mice on high-fat diet.","Over 10% of islet cells expressed GLP-1 after single dose; no safety signals.","Data independently validated by Dr. Randy Seeley at University of Michigan.","Fractyl plans to use durable efficacy results for RJVA-001 FIH data package."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120706","json":"https://secwatch.observer/filing/0000950170-24-120706.json","markdown":"https://secwatch.observer/filing/0000950170-24-120706.md","text":"https://secwatch.observer/filing/0000950170-24-120706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000095017024120706/0000950170-24-120706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000095017024120706/guts-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:02:26.047655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}